NAPSR News: Chimerix’s experimental drug Brincidofovir used to treat Ebola patients

WASHINGTON - Oct. 8, 2014 - PRLog -- On October 6, 2014, Chrimerix Inc had announced that the U.S. Food and Drug Administration (FDA) had granted Emergency Investigational New Drug Applications (EIND) for  brincidofovir to treat ebola patients. Brincidofovir, is an oral nucleotide analog that has demonstrated in vitro antiviral activity against all five families of DNA viruses that affect humans, including viruses in the herpes virus family and adenovirus.

"Chimerix is committed to working with global health organizations and government agencies in the fight against the Ebola virus outbreak," said M. Michelle Berrey, M.D., M.P.H., President and Chief Executive Officer of Chimerix. "Based on in vitro data from work conducted by the CDC and the National Institutes of Health suggesting brincidofovir's activity against Ebola, we are hopeful that brincidofovir may offer a potential treatment for Ebola Virus Disease during this outbreak. Data collected over years of clinical development of brincidofovir have allowed us to progress this compound into Phase 3 programs for cytomegalovirus and adenovirus infections, and provided information on the safety and dosing of brincidofovir to allow it to be explored as a potential therapy for Ebola Virus Disease."

UPDATE: Thomas Duncan – the Texas patient who contracted the virus in Liberia and who was already in critical condition was given the experimental treatment on Saturday, regrettably after battling the virus for weeks he passed away today. Freelance video journalist Ashoka Mukpo, is currently receiving the experimental treatment in Nebraska. He contracted Ebola while working with  Dr. Nancy Snyderman on assignment for NBC News.

Chimerix has been working with the FDA to proceed with the Advise Phase 3 clinical trial to evaluate the safety and efficacy of brincidofovir for the treatment of adenovirus infection. The company has also collaborated with the Biomedical Advanced Research and Development Authority (BARDA) to develop brincidofovir as a medical countermeasure against smallpox.

The NAPSRx® is a trade association for pharmaceutical sales reps, sales managers and sales trainers who work in the pharmaceutical industry. NAPSRx® provides Continuing Medical Education to its members as well as CNPR® Certification to candidates who look to enter a pharmaceutical sales career. The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals.

The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information or visit the website at http://napsronline.org/.